A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Korean data of treating EGFR mutation positive NSCLC patients with Erlotinib and Bevacizumab
is significantly necessary for developing new standard treatment in first-line therapy in
Korean EGFR mutant NSCLC patients.
In this study, The investigators will investigate the efficacy and safety of Erlotinib and
Bevacizumab combination compare to Erlotinib alone in Korean EGFR-mutant NSCLC patients.